The Pharmacy Times® Ovarian Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to the group of diseases that originates in the ovaries, fallopian tubes, or the peritoneum.
March 22nd 2024
The treatment is indicated for patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Exercise Can Improve Chemotherapy-Induced Peripheral Neuropathy in Patients With Ovarian Cancer
August 4th 2023The affect of an aerobic exercise program was more prevalent in patients with ovarian cancer who had at least 1 symptom of chemotherapy-induced peripheral neuropathy at the beginning of the trial.
Read More
Clinical Overview: The Addition of Curcumin to Standard Ovarian Cancer Chemotherapy
For the management of ovarian cancer, it has been observed in both cellular and animal models that curcumin suppresses cell proliferation and promotes apoptosis.
Read More
FDA Approves Bevacizumab Biosimilar for Six Types of Cancer
September 28th 2022Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More